<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Anaphylaxis - ACLS - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Anaphylaxis</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../../index.html">Home</a>
        <a class="btn small" href="../../acls.html">Back to ACLS</a>
        <a class="btn small" href="../../acls_special.html">Back to Special Situations</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">ACLS Special Situation</div>
      <h1>Anaphylaxis</h1>

      <div class="content">
        <h2>Entry criteria (treat if suspected)</h2>
        <ul>
          <li>Sudden illness after likely allergen exposure WITH any of:
            <ul>
              <li>Airway: throat tightness, hoarseness/stridor, tongue/lip swelling</li>
              <li>Breathing: wheeze, increased work of breathing, hypoxemia</li>
              <li>Circulation: hypotension, collapse, syncope, shock</li>
              <li>OR skin/mucosal features (hives, flushing, angioedema) PLUS respiratory or cardiovascular involvement</li>
            </ul>
          </li>
          <li>If in doubt and there is airway/breathing/circulation compromise: treat as anaphylaxis</li>
        </ul>

        <h2>Immediate actions (first moments)</h2>
        <ul>
          <li>Call for help; assign roles; prepare for rapid deterioration</li>
          <li>Position:
            <ul>
              <li>Keep patient supine (or left lateral if pregnant); elevate legs if hypotensive</li>
              <li>Avoid sudden standing/sitting (can precipitate collapse)</li>
            </ul>
          </li>
          <li>Remove trigger if possible (stop infusion, remove stinger)</li>
          <li>Airway/Breathing:
            <ul>
              <li>High-flow oxygen as needed</li>
              <li>Prepare early for airway edema (difficult airway risk)</li>
            </ul>
          </li>
          <li>Circulation:
            <ul>
              <li>Establish IV access; start fluid resuscitation if hypotensive</li>
            </ul>
          </li>
          <li>Monitoring:
            <ul>
              <li>Continuous ECG, SpO₂, BP; consider waveform capnography if ventilated</li>
            </ul>
          </li>
        </ul>

        <h2>First-line medication (do not delay)</h2>
        <ul>
          <li>Epinephrine IM (preferred)
            <ul>
              <li>Adult: 0.5 mg IM (0.5 mL of 1 mg/mL [1:1000]) into mid-anterolateral thigh</li>
              <li>Repeat every 5–15 minutes as needed based on symptoms and response</li>
              <li>If an auto-injector is the only option available: use it immediately and repeat as per device availability/clinical response</li>
            </ul>
          </li>
        </ul>

        <h2>Core cycle (repeat and reassess)</h2>
        <ol>
          <li>Give IM epinephrine promptly</li>
          <li>Reassess airway/breathing/circulation within minutes</li>
          <li>Repeat IM epinephrine if ongoing airway/breathing compromise or hypotension</li>
          <li>Treat shock aggressively with IV fluids</li>
          <li>Escalate early if refractory (see below)</li>
        </ol>

        <h2>Fluids (for hypotension/shock)</h2>
        <ul>
          <li>Give rapid isotonic crystalloid bolus; reassess frequently</li>
          <li>Ongoing shock may require repeated boluses (VERIFY typical adult bolus volumes per your local protocol)</li>
        </ul>

        <h2>Adjuncts (NOT substitutes for epinephrine)</h2>
        <ul>
          <li>Bronchospasm:
            <ul>
              <li>Inhaled beta-agonist (e.g., salbutamol) for wheeze/bronchospasm</li>
            </ul>
          </li>
          <li>Cutaneous symptoms:
            <ul>
              <li>H1 antihistamine can help hives/itch but does not treat airway/shock</li>
            </ul>
          </li>
          <li>Steroids:
            <ul>
              <li>May be used as an adjunct; do not delay epinephrine (benefit for biphasic reaction prevention is uncertain)</li>
            </ul>
          </li>
          <li>Consider glucagon if patient on beta-blocker with refractory hypotension/bronchospasm (VERIFY dosing/prep per protocol)</li>
        </ul>

        <h2>Refractory anaphylaxis (escalation)</h2>
        <ul>
          <li>Definition (practical): persistent respiratory compromise or hypotension despite:
            <ul>
              <li>Repeated IM epinephrine (e.g., 2–3 doses) AND</li>
              <li>Adequate fluid resuscitation</li>
            </ul>
          </li>
          <li>Actions:
            <ul>
              <li>Begin epinephrine IV infusion if trained/equipped (VERIFY local infusion concentration/rate and pump availability)</li>
              <li>Seek senior consult early; prioritize airway control if worsening edema/stridor</li>
              <li>AVOID IV epinephrine bolus dosing unless in a monitored setting with expert support (higher adverse event risk)</li>
            </ul>
          </li>
        </ul>

        <h2>Airway red flags (act early)</h2>
        <ul>
          <li>Rapidly progressive tongue/oropharyngeal swelling</li>
          <li>Stridor/voice change</li>
          <li>Inability to swallow secretions</li>
          <li>Worsening respiratory distress despite IM epinephrine</li>
          <li>If present: prepare for early advanced airway with best available expertise and backup plan</li>
        </ul>

        <h2>Observation / recurrence risk</h2>
        <ul>
          <li>Symptoms can recur (biphasic reaction). Observe and reassess after stabilization.</li>
          <li>Provide discharge planning when appropriate:
            <ul>
              <li>Trigger avoidance + follow-up</li>
              <li>Epinephrine auto-injector planning if applicable (VERIFY local pathway)</li>
            </ul>
          </li>
        </ul>

        <h2>Exit paths</h2>
        <ul>
          <li>Improved and stable after treatment → monitor/observe, document, plan follow-up and prevention</li>
          <li>Persistent instability or airway risk → escalate/transfer planning (at-sea: early discussion for MEDEVAC triggers)</li>
          <li>Cardiorespiratory arrest → transition to ACLS arrest algorithms</li>
        </ul>
      </div>
    </section>
  </main>
</body>
</html>
